Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer.
about
Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of gefitinib effica ...... ed non-small cell lung cancer.
@en
Evaluation of gefitinib effica ...... ed non-small cell lung cancer.
@nl
type
label
Evaluation of gefitinib effica ...... ed non-small cell lung cancer.
@en
Evaluation of gefitinib effica ...... ed non-small cell lung cancer.
@nl
prefLabel
Evaluation of gefitinib effica ...... ed non-small cell lung cancer.
@en
Evaluation of gefitinib effica ...... ed non-small cell lung cancer.
@nl
P2093
P2860
P1476
Evaluation of gefitinib effica ...... ed non-small cell lung cancer.
@en
P2093
Akira Mogi
Atsushi Takise
Hisao Imai
Kaori Seki
Kimihiro Shimizu
Koichi Minato
Kyoichi Kaira
Masanobu Yamada
Mitsuyoshi Utsugi
Noriaki Sunaga
P2860
P2888
P304
P356
10.1007/S00280-016-3232-2
P577
2017-02-06T00:00:00Z